Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib plus chemotherapy in newly treated extranodal DLBCL (MCD subtype)
ChiCTR2200060370Phase 4Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of zanubrutinib in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Peking University Third Hospital. Primary endpoints: Overall response rate after 2 cycles and Overall response rate after 6 cycles. Planned start May 2022; status: not yet recruiting.
02
Drugs
zanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2200060370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060370.